Established rheumatoid arthritis

Bailliere's Best Practice and Research in Clinical Rheumatology

Volumn 13, Issue 4, 1999, Pages 561-575

  Conaghan, Philip G ^a   Green, Michael J ^a   Emery, Paul ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Diagnosis; Early; Established; Natural history; Prognosis; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT; C REACTIVE PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; RHEUMATOID FACTOR;

DISEASE COURSE; DISEASE DURATION; HUMAN; JOINT INJURY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RHEUMATOID ARTHRITIS;

EID: 0033387126     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1053/berh.1999.0046     Document Type: Article

References (59)

1. Arnett F C, Edworthy S M, Bloch D A. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis and Rheumatism. 31:1988;315-324.
2. Harrison B J, Symmons D PM, Barrett E M, Silman A J. The performance of the 1987 ARA classification criteria for rheumatoid arthritis in a population based cohort of patients with early inflammatory arthritis. Journal of Rheumatology. 25:1998;2324-2330.
3. Green M J, Marzo H, Proudman S. Remission and relapse in early synovitis patients post treatment with Depomedrone: time dependent effect of ACR criteria and CRP on outcome. British Journal of Rheumatology. 37:1998;S121.
4. Conaghan P G, Wakefield R J, O'Connor P. MCPJ assessment in early RA: a comparison between Xray. MRI, high resolution ultrasound and clinical examination. Arthritis and Rheumatism. 41:1998;S246.
5. Wakefield R J, Green M J, Gibbon W W. High resolution ultrasound defined subclinical synovitis - a predictor of outcome in early oligoarthritis? Arthritis and Rheumatism. 41:1998;S246.
6. Emery P. The optimal management of early rheumatoid disease: the key to preventing disability. British Journal of Rheumatology. 33:1994;765-768.
7. Porter D R, Capell H A. The 'natural' history of active rheumatoid arthritis over 3-6 months - an analysis of patients enroled into trials of potential disease-modifying anti-rheumatic drugs, and treated with placebo. British Journal of Rheumatology. 32:1993;463-466.
8. Pincus T, Callahan L F. What is the natural history of rheumatoid arthritis? Rheumatic Disease Clinics of North America. 19:1993;123-151.
9. Wolfe F. The natural history of rheumatoid arthritis. Journal of Rheumatology. 23:1996;13-22.
10. Cooper C, Wickham C. Rheumatoid arthritis, corticosteroid therapy and hip fracture. Christiansen C, Overgaard K. Osteoporosis. 1990;1578-1589 Osteopress, Copenhagen.
11. Spector T, Hall G M, McCloskey E V, Kanis J A. Risk of vertebral fracture in women with rheumatoid arthritis. British Medical Journal. 306:1993;558.
12. Gough A KS, Lilley J, Eyre S. Generalised bone loss in patients with early rheumatoid arthritis. Lancet. 344:1994;23-27.
13. Conaghan P G, Crotty M, Oh E. Anti-rheumatic drug-prescribing behaviour of Australian rheumatologists 1984-1994. British Journal of Rheumatology. 36:1997;487-490.
14. Galindo-Rodriguez G, Avina-Zubieta J A, Fitzgerald A. Variations and trends in the prescription of initial second line therapy for patients with rheumatoid arthritis. Journal of Rheumatology. 24:1997;633-638.
15. Ward M M, Fries J F. Trends in antirheumatic medication use among patients with rheumatoid arthritis, 1981-1996. Journal of Rheumatology. 25:1998;408-416.
16. Fries J F. Reevaluating the therapeutic approach to rheumatoid arthritis: the 'sawtooth' strategy. Journal of Rheumatology. 17:1990;12-15.
17. Wilske K R, Healey L A. Remodeling the pyramid: a concept whose time has come. Journal of Rheumatology. 16:1989;565-567.
18. Maetzel A, Bombardier C, Strand V. How Canadian and US rheumatologists treat moderate or aggressive rheumatoid arthritis: a survey. Journal of Rheumatology. 25:1998;2331-2338.
19. Verhoeven A C, Boers M, Tugwell P. Combination therapy in rheumatoid arthritis: updated systematic review. British Journal of Rheumatology. 37:1998;612-619.
20. Fries J F, Williams C A, Morfeld D. Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies. Arthritis and Rheumatism. 39:1996;616-622.
21. Mottonen T, Hannonen P, Leirisalo-Repo M. Prediction of remission in early rheumatoid arthritis. Arthritis and Rheumatism. 41:1998;S238.
22. Abu-Shakra M, Toker R, Flusser D. Clinical and radiographic outcomes of rheumatoid arthritis patients not treated with disease-modifying drugs. Arthritis and Rheumatism. 41:1998;1190-1195.
23. van der Heide A, Jacobs J WG, Bijlsma J WJ. The effectiveness of early treatment with 'second-line' antirheumatic drugs. A randomised controlled trial. Annals of Internal Medicine. 124:1996;699-707.
24. Egsmose C, Lund B, Borg G. Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year follow up of a prospective double blind placebo controlled study. Journal of Rheumatology. 22:1995;2208-2213.
25. Munro R, Hampson R, McEntegart A. Improved functional outcome in patients with early rheumatoid arthritis treated with intramuscular gold: results of a five year prospective study. Annals of the Rheumatic Diseases. 57:1998;88-93.
26. van Zeben D, Breedveld F C. Prognostic factors in rheumatoid arthritis. Journal of Rheumatology. 44:1996;31-33.
27. Amos R S, Constable T J, Crockson R A. Rheumatoid arthritis: relation of serum C-reactive protein and erythrocyte sedimentation rates to radiographic changes. British Medical Journal. 1:1977;195-197.
28. Scott D L, Coulton B L, Symmons D PL, Poppert A J. Long term outcome of treating rheumatoid arthritis: results after 20 years. Lancet. 330:1987;1108-1111.
29. Dawes P T, Fowler P D, Clarke S. Rheumatoid arthritis: treatment which controls the C-reactive protein and erythrocyte sedimentation rate reduces radiological progression. British Journal of Rheumatology. 25:1986;44-49.
30. van Leeuwen M A, van Rijswijk M H, van der Heijde D FM. The acute phase response in relation to radiographic progression in early rheumatoid arthritis: a prospective study during the first three years of treatment. British Journal of Rheumatology. 329:1993;9-13.
31. Devlin J, Gough A, Huissoon A. The acute phase and function in early rheumatoid arthritis. CRP levels correlate with functional outcome. Journal of Rheumatology. 24:1997;9-13.
32. Wolheim F A. Biochemical markers of joint tissue destruction in rheumatoid arthritis. Rheumatology in Europe 2. 1995;173-175.
33. Poole A R. Biological markers in rheumatoid arthritis. Seminars in Arthritis and Rheumatism. 23:1994;17-31.
34. Gough A KS, Peel N FA, Eastall R. Excretion of pyridinium crosslinks correlates with disease activity and appendicular bone loss in early rheumatoid arthritis. Annals of Rheumatic Diseases. 53:1994;14-17.
35. Fex E, Eberhardt K, Saxne T. Tissue derived macromolecules and markers of inflammation in serum in early rheumatoid arthritis: Relationship to development of joint destruction in the hands and feet. British Journal of Rheumatology. 36:1997;1161-1165.
36. Peel N FA, Spittlehouse A J, Bax D E, Eastell R. Bone mineral density of the hand in rheumatoid arthritis. Arthritis and Rheumatism. 37:1994;983-991.
37. Green M J, Proudman S, Stewart S. Serial hand bone densitometry with Lunar-XL densitometer in the assessment of patients with very early inflammatory arthritis. British Journal of Rheumatology. 37:1998;S104.
38. Deodhar A A, Brabyn J, Pande I. A five years longitudinal study of hand bone densitometry in early rheumatoid arthritis. Arthritis and Rheumatism. 41:1998;S52.
39. Wolfe F, Kleinheksel S M, Cathey M A. The clinical value of the Stanford Health Assessment Questionnaire Functional Disability Index in patients with rheumatoid arthritis. Journal of Rheumatology. 15:1988;1480-1488.
40. Leigh J P, Fries J F. Predictors of disability in a longitudinal sample of patients with rheumatoid arthritis. Annals of Rheumatic Diseases. 51:1992;581-587.
41. van der Heijde D MFM, van Riel P LCM, van Rijswijk M H, van de Putte L BA. Influence of prognostic factors on the final outcome in rheumatoid arthritis: A review of the literature. Seminars in Arthritis and Rheumatism. 17:1988;284-292.
42. Woolf A D, Hall N D, Goulding N J. Predictors of the long term outcome of early synovitis: A 5 year follow up study. British Journal of Rheumatology. 30:1991;251-254.
43. Corbett M, Dalton S, Young A. Factors predicting death, survival and functional outcome in a prospective study of early rheumatoid disease over fifteen years. British Journal of Rheumatology. 32:1993;717-723.
44. van Schaardenburg D, Hazes D M, de Boer A. Outcome of rheumatoid arthritis in relation to age and rheumatoid factor at diagnosis. Journal of Rheumatology. 20:1993;45-52.
45. Gough A, Faint J, Salmon M. Genetic typing of patients with inflammatory arthritis at presentation can be used to predict outcome. Arthritis and Rheumatism. 37:1994;1166-1170.
46. Paimela L, Palosuo T, Leirisalo-Repo M. Prognostic value of quantitative measurement of rheumatoid factor in early rheumatoid arthritis. British Journal of Rheumatology. 34:1995;1146-1150.
47. Eberhart K B, Trusdsson L, Petterson H. Disease activity and joint damage progression in early rheumatoid arthritis and relation to IgG, IgA, and IgM rheumatoid factor. Annals of Rheumatic Diseases. 49:1990;906-909.
48. Vincent C, Simon M, Sebbag M. Immunoblotting detection of autoantibodies to human epidermis filaggrin: a new diagnostic test for rheumatoid arthritis. Journal of Rheumatology. 25:1998;838-846.
49. Westedt M L, Daha M, Baldwin W M. Serumimmune complexes containing IgA appear to predict erosive arthritis in a longitudinal study in rheumatoid arthritis. Annals of the Rheumatic Diseases. 45:1986;809-815.
50. van Zeben D, Rook G AW, Hazes J MW. Early agalactosylation of IgG is associated with a more progressive disease course in patients with rheumatoid arthritis: Results of a follow up study. British Journal of Rheumatology. 33:1994;36-43.
51. Young A, Smuar N, Bodman K. Agalctosyl IgG: An aid to differential diagnosis in early synovitis. Arthritis and Rheumatism. 34:1991;1425-1429.
52. Cook A, Rowley J M, Mackay I R. Antibodies to type II collagen in early rheumatoid arthritis: correlation with disease progression. Arthritis and Rheumatism. 39:1996;1720-1727.
53. Emery P, Salmon M, Bradley H. Genetically determined factors as predictors of radiological change in patients with early symmetrical arthritis. British Medical Journal. 305:1992;1387-1389.
54. Wordsworth B P, Salmon M. The HLA class II component of susceptibility to rheumatoid arthritis. Baillière's Clinical Rheumatology. 6:1992;325-327.
55. Silman A J, Reeback J, Jaraquemada D. HLA-DR4 as a predictor of outcome three years after onset of rheumatoid arthritis. Rheumatology International. 6:1986;233-235.
56. Paimela L, Leirsalo-Repo M, Helve T. The prognostic value of HLA DR4 and B27 antigens in early rheumatoid arthritis. Scandinavian Journal of Rheumatology. 22:1993;220-224.
57. van Zeben D. Factors predicting outcome of rheumatoid arthritis, results of a follow up study. Journal of Rheumatology. 20:1993;1288-1296.
58. O'Dell J R, Nepom B S, Haire C. HLA-DRB1 typing in rheumatoid arthritis: predicting response to specific treatments. Annals of Rheumatic Diseases. 57:1998;209-213.
59. Mottonen T, Paimela L, Ahonen J. Outcome in patients with earl rheumatoid arthritis treated according to the "sawtooth" strategy. Arthritis and Rheumatism. 39:1996;996-1005.